Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials-Reference-Cited by-同舟云学术

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials

Published:2013-03 Issue:4 Volume:49 Page:769-781
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bellera Carine A.,Pulido Marina,Gourgou Sophie,Collette Laurence,Doussau Adélaïde,Kramar Andrew,Dabakuyo Tienhan Sandrine,Ouali Monia,Auperin Anne,Filleron Thomas,Fortpied Catherine,Le Tourneau Christophe,Paoletti Xavier,Mauer Murielle,Mathoulin-Pélissier Simone,Bonnetain Franck

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Endpoints for assessing drug activity in clinical trials;Pazdur;Oncologist,2008

2. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy – an Aide et Recherche en Cancerologie Digestive Group Study;Chibaudel;J Clin Oncol,2011

3. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer;Le Tourneau;J Clin Oncol,2009

4. Survival end point reporting in randomized cancer clinical trials: a review of major journals;Mathoulin-Pelissier;J Clin Oncol,2008

5. End points and United States Food and Drug Administration approval of oncology drugs;Johnson;J Clin Oncol,2003

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

2. Evaluation of Time-to-event Surrogate Endpoint Endpoint ─Meta-analytic Approach─;Japanese Journal of Biometrics;2024-07-30

3. Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations;The Lancet Oncology;2024-07

4. Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations;The Lancet Oncology;2024-07

5. Assessing patient-reported outcomes (PROs) and patient-related outcomes in randomized cancer clinical trials for older adults: Results of DATECAN-ELDERLY initiative;Journal of Geriatric Oncology;2024-01